XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study
to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and
pharmacodynamics (PD) of orally administered XW014 in healthy participants and patients with
T2DM. This study will consist of 3 parts: a Single Ascending Dose (SAD) part in healthy
subjects (Part A), and Multiple Ascending Dose (MAD) parts in healthy subjects with elevated
BMI (Part B) and patients with T2DM (Part C).